Industry News
Biotechnology Industry News
Viking Therapeutics’…
Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to jettison part of the pact.
Johnson & Johnson has dropped…
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.
“We want to develop those programs…
"We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce.
Amgen has pulled the plug on…
Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating five clinical trials in the process.
As MRD shifts from prognostic…
As MRD shifts from prognostic marker to intervention trigger, sponsors must rethink trial design, endpoints and decision-making.
After last month’s departure of…
After last month’s departure of longtime executive Adam Pearson, Astellas has picked out a new strategist to fill the open spot on its C-suite with Takahiko Iwaya, who takes over as chief strategy officer on
Curium’s Mike Patterson on…
Curium’s Mike Patterson on improving access, safety and trust to scale theranostics and enhance patient care.
An FDA expert panel on Thursday…
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative metastatic breast cancer, dealing an early blow
The Trump administration’s support…
The Trump administration's support could launch psychedelics across the regulatory finish line or doom the field to perpetual questions of legitimacy.
Bristol Myers Squibb has called…
Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from Celgene.
Indivior ended internal…
Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
BeOne Medicines is paying $20…
BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.
Danish dermatology specialist Leo…
Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene therapy for a rare skin disease.
GSK and Alector have stopped a…
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint.
Avalyn Pharma has overshot its…
Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.
AstraZeneca has paid $25 million…
AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with Pinetree Therapeutics.
The FDA has halted U.S. enrollment…
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside of the country.
AstraZeneca has announced it will…
AstraZeneca has announced it will resume a £300 million investment program in the U.K., seven months after freezing the plans in frustration at national government drug pricing negotiations.
Teva Pharmaceuticals has struck a…
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the drugmaker to advance a Tourette syndrome candidate that is on the cusp of approval.
AstraZeneca has scrapped an asthma…
AstraZeneca has scrapped an asthma program after the FLAP inhibitor flunked a phase 2 trial.